In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 151 to 160 of 389

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]	Technology appraisal guidance	TBC
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]	Technology appraisal guidance	TBC
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]	Technology appraisal guidance	TBC
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Implanting a baroreceptor stimulation device for resistant hypertension	Interventional procedures guidance	TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]	Technology appraisal guidance	TBC
In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death	Interventional procedures guidance	19 November 2026
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]	Technology appraisal guidance	TBC

Results per page

10
25
50
All